Podcasts about Drug policy

Send us a textIn this week's episode of Cannabis Legalization News, we dive into the latest news on cannabis legalization, including updates on DEA policies, the Trump Administration's drug policy for 2025, and new developments in Texas' hemp industry. We discuss the absence of marijuana in the Trump Administration's drug policy, the struggles of the cannabis market in Illinois, the implications of the farm bill, and address fears around driving under the influence of cannabis. Additionally, we touch on significant court cases, economic studies, and how federal background check issues are affecting Delaware's cannabis licensing. Tune in for an in-depth analysis and discussion on the complexities of cannabis regulation and industry challenges.00:00 Introduction and Weekly Cannabis News00:50 Trump Administration's Drug Policy for 202504:21 Endocannabinoid Systems and Online Dispensaries07:27 Challenges in the Hemp Market11:52 Supreme Court Ruling on CBD Mislabeling17:16 Cannabis Economics and Market Analysis23:04 Federal Legalization and Interstate Commerce30:51 Lucas Roy Case and Legal Challenges34:35 Republicans and Hemp Rights35:25 Cannabis Use Disorder and Legal Challenges36:36 Trucking and Marijuana Testing Protocols40:48 Texas Hemp Legislation44:02 Hemp Market and Regulation Issues56:16 Delaware's Recreational Marijuana Background Checks59:14 Minnesota and Michigan Cannabis Markets01:03:21 Pro-Marijuana Ads Targeting TrumpSupport the show

For the second year in a row, what had been an uneventful, consensus-driven United Nations meeting on drug policy saw unexpected drama and signs of real change. At the 68th session of the UN Commission on Narcotic Drugs (CND) in Vienna in March 2025, governments approved the formation of an independent expert commission to recommend changes to the architecture of global drug policy, which has changed little since the early 1960s. Colombia again played a catalytic role, as it did in 2024. But this time, the United States—under the new Trump administration—tried to block nearly everything, isolating itself diplomatically in the process. In this episode of the WOLA Podcast, Adam Isacson speaks with three experts who were in Vienna: Ann Fordham, Executive Director of the International Drug Policy Consortium (IDPC), a network of 195 organizations working to reform global drug policy. Isabel Pereira, Senior Coordinator for drug policy at DeJusticia, a Bogotá-based think tank and advocacy group. John Walsh, WOLA's Director for Drug Policy, who has tracked the UN's drug control system since the 1980s. The conversation traces the slow evolution of the UN drug control system—from decades of punitive consensus to today's shifting coalitions, unprecedented votes, and long-overdue reviews. Much of the episode centers on a breakthrough: a new resolution establishing an “independent external review” of the UN's own drug control institutions. For years, countries like Colombia have called for an honest assessment of the system's failings. Now, thanks to a resolution spearheaded by Colombia and passed over U.S. opposition, that review is happening. The details still matter: how independent the expert panel will truly be, who funds it, and whether the review can influence the hard architecture of the drug control treaties. “Vienna was very much a space where delegates would just pat each other on the back on how well we're doing the war on drugs,” Pereira said. “The spirit of Vienna created a sort of lockdown situation on debate, true debate,” added Walsh. “Civil society enlivened the Vienna atmosphere” in recent years, he noted, “with new debates, new arguments.” Now, this international space has become more dynamic. The guests also discuss coca leaf: its decades-old listing as a Schedule I narcotic, Bolivia's and Colombia's ongoing push for a scientific review, and the possibility of a pivotal vote in 2026. They stress how traditional knowledge—especially from Indigenous communities—must be recognized as legitimate scientific input during that review. Underlying it all is a major diplomatic shift. Colombia is using the UN system to demand drug policy grounded in health, human rights, and development—not militarized prohibition. But with Petro's term ending in 2026, it's unclear who will pick up the baton. Meanwhile, the Trump administration is signaling a return to zero-tolerance drug war policies—and burning bridges with potential allies in the process. “They behaved so terribly. I mean, they broke with all diplomatic niceties,” said Fordham. “The U.S. just went for it in their opening statement… It was frankly an embarrassing, but also pretty shocking statement.” Despite the uncertainty, all three guests agree: civil society is no longer on the sidelines. NGOs and experts are shaping debates, challenging rigid thinking in Vienna, and holding governments to account.

Robert Forte is a scholar of the history and psychology of religion, with a special focus on the ancient and modern use—and misuse—of psychedelic plants and drugs. He has studied and collaborated with many of the most seminal figures who first brought these substances to public consciousness since the 1940s, including Albert Hofmann, Gordon Wasson, Timothy Leary, Alexander Shulgin, Stanislav Grof, and others.His first book, Entheogens and the Future of Religion, was praised by Huston Smith as “the best single inquiry into the religious significance of psychedelics.” His second book, Outside Looking In: Appreciations, Castigations, Reminiscences of Timothy Leary, offers an intimate look at this controversial figure. In 1998, he republished an updated edition of The Road to Eleusis: Unveiling the Secret of the Mysteries by Gordon Wasson, Albert Hofmann, and Carl Ruck—a seminal text that initiated the inquiry into the role of entheogens in Western religion and philosophy.Over the years, Forte has manufactured MDMA before it was scheduled, conducted research into its clinical effects, and performed fieldwork in Peru studying the impact of ayahuasca on cancer patients. He has also maintained an underground practice utilizing various medicines for psychotherapy and spiritual exploration.Around 20 years ago, his interests shifted toward the sociology of psychedelic experience, where he has developed a somewhat controversial perspective on how these substances entered modern consciousness. He argues that the history of psychedelics, much like the history of religion, contains both the best and worst of humanity. Without acknowledging and integrating its shadow aspects, he warns, we risk becoming victims of them.Episode Highlights▶ How early psychedelic experiences profoundly influenced individual perspectives.▶  How the 1980s saw a resurgence in psychedelic research following prior suppression.▶  MDMA's shift from therapeutic tool to illegal substance exemplifies drug policy complexities.▶  Government drug policies and how they often prioritize control over public health.▶  The psychedelic narratives that are often entangled with conspiracy theories and misinformation.▶  How psychedelics offer potential for consciousness expansion, but require careful integration to avoid pitfalls like spiritual bypassing.▶  The Controlled Substances Act and how it's rationality is widely questioned.▶  How despite illegality, MDMA's popularity grew, reflecting societal interest.▶  The societal impact of psychedelics is multifaceted, demanding ethical consideration.▶  Why meaningful change requires applying psychedelic insights to daily life, beyond mere experience.Robert Forte's Links & Resources▶ Website: alteredstatesofamerica.net▶ Substack: alteredstatesofamerica.substack.com▶ Facebook: https://web.facebook.com/robert.forte.79  Download Beth's free trainings here: Clarity to Clients: Start & Grow a Transformational Coaching, Healing, Spiritual, or Psychedelic Business: https://bethaweinstein.com/grow-your-spiritual-businessIntegrating Psychedelics & Sacred Medicines Into Business: https://bethaweinstein.com/psychedelics-in-business▶ Beth's Coaching & Guidance: https://bethaweinstein.com/coaching ▶ Beth's Offerings & Courses: https://bethaweinstein.com/services▶ Instagram: @bethaweinstein ▶ FB: / bethw.nyc + bethweinsteinbiz ▶ Join the free Psychedelics & Purpose Community: / psychedelicsandsacredmedicines

Jerry talks to Bob Richardson in Party For Two, Jerry discusses a couple of new stories around safe consumption sites, a GO Transit emergency has us asking questions about response times, and Dan McTeague, President of Canadians for Affordable Energy talks about the cuts and promises of the carbon tax.

In this episode, I travel to Joliet, Illinois, to sit down with Senator Rachel Ventura. We discuss her groundbreaking legislation that could end vehicle searches based solely on the smell of cannabis, a longstanding issue impacting cannabis consumers across Illinois. Senator Ventura shares the story behind the bill, the challenges with current laws, and how her advocacy intersects with criminal justice reform and environmental policy. Watch video version and read full show notes here: https://thecolememo.com/2025/03/21/e179/

A Conversation on Historical Crimes and Modern Impacts: From Poaching to MassacresIn this captivating episode of our true crime podcast, join hosts Tom and Simon as they dive deep into history's most shocking crimes and the evolution of criminal psychology. Tom and Simon reconnect after a recent live Crime Time Inc podcast event in Glasgow, where they discuss memorable moments from the night. The episode takes you back to 1984 with the cold case resolution of Mary McLaughlin's murder, thanks to innovative forensic techniques. Move forward in time to revisit the rampages of Derek Bird and Michael Ryan, analyzing their impacts on firearm legislation and police responses. Get a historical perspective on violent poaching in 1876 and its deadly consequences for law enforcement. Experience the notorious scandals of Hollywood with Fatty Arbuckle and the shocking assassination aftermath of JFK, exploring the mysterious actions of Jack Ruby. This episode offers an extensive range of topics sure to engage both hardcore true crime enthusiasts and casual listeners. Tune in to explore these unsolved mysteries, infamous murders, and much more!00:00 Reunion and Glasgow Traffic Woes00:32 Reflecting on the Mitchell Library Event01:00 Exploring the Madeleine Smith Exhibit02:44 True Crime Quiz: Griselda Blanco04:53 Upcoming Season and Personal Updates06:27 Case Discussion: Mary McLaughlin11:03 Homicide Governance Review Team13:24 Live Podcast Promotion14:03 Case Discussion: Cumbria Shootings25:45 Poaching and Historical Policing33:51 Hungerford Massacre: The Impact of Michael Ryan34:35 The Evolution of Firearms Laws in the UK37:00 The Rise of Knife Crime and Offensive Weapons44:42 The Case of Fatty Arbuckle: A Hollywood Scandal55:18 JFK Assassination: The Aftermath and Conspiracies01:01:38 Violence Reduction and Drug Policy in Scotland01:05:02 Season Review and Upcoming PlansTom Wood is a former murder squad detective and Deputy Chief Constable of Lothian and Borders Police in Scotland. Tom worked on many high profile murder cases including Robert Black, Peter Tobin and was part of the team investigating The World's End Murders from day one until 37 years later when the culprit, Angus Sinclair was finally convicted. Tom was latterly the detective in overall charge of The World's End murder investigation. Tom is now retired from the Police and is a successful author.Tom Wood's Books Ruxton: The First Modern Murder https://amzn.eu/d/25k8KqGThe World's End Murders: The Inside Story https://amzn.eu/d/5U9nLoPSimon is the best selling author of The Ten Percent, https://amzn.eu/d/5trz6bs a memoir consisting ofstories from the first part of his career as a police officer. From joining in 1978,being posted in Campbeltown in Argylll, becoming a detective on the Isle ofBute, Scotland, through to the Serious Crime Squad and working in the busy Glasgowstation in Govan, Hosted on Acast. See acast.com/privacy for more information.

Drug policy in America is at a critical inflection point. Following a period dominated by extreme harm reduction approaches, we're witnessing a significant shift back toward accountability-based treatment models. This transformation comes as cities like San Francisco and states like Oregon roll back failed experiments that provided tools for addiction without addressing its root causes.Dr. Kevin Sabet joins us fresh from United Nations meetings in Vienna, where American representation was noticeably diminished – a symptom of the current administration's still-developing drug policy strategy. Together, we analyze Dr. Nora Volkow's recent Stat News interview, where the longtime NIDA Director expressed skepticism about universalizing 12-step approaches despite compelling research supporting their effectiveness. As Sabet points out, studies from leading institutions demonstrate that 12-step programs often outperform traditional psychotherapy while lowering healthcare costs.The encouraging decline in opioid overdose deaths presents a complex puzzle we attempt to unravel. Is it increased naloxone availability? Greater public awareness of fentanyl dangers? The tragic reality that many vulnerable users have already died? The answer likely combines these factors, highlighting why comprehensive approaches that blend harm reduction tools with accountability-focused recovery pathways remain essential. As America recalibrates its drug policy strategy, this conversation offers crucial context for understanding what works, what doesn't, and why the pendulum is swinging back toward treatment models that emphasize personal responsibility alongside compassionate care.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

What transforms a tough-on-crime conservative Christian from Mississippi into a powerful advocate for drug policy reform? For Christina Dent, it was her experience as a foster mom. That launched her on a path to found End It For Good, an organization fighting to revolutionize America's approach to drugs. From sharing her personal story to working with lawmakers, Christina challenges us to question our assumptions about drugs and addiction and imagine a different path forward. To learn more about Christina’s story and how to get involved, check out her book, Curious: A Foster Mom's Discovery of an Unexpected Solution to Drugs and Addiction, and visit enditforgood.com Follow When it Clicked wherever you get your podcasts, or listen ad-free on Amazon Music with your Prime Membership. Stay up to date with us on Twitter, Facebook and Instagram at @LemonadaMedia. Want to become a Lemonada superfan? Join us at joinsubtext.com/lemonadasuperfan. Click this link for a list of current sponsors and discount codes for this and all other Lemonada series: lemonadamedia.com/sponsors. To follow along with a transcript, go to lemonadamedia.com/show/ shortly after the air date. See omnystudio.com/listener for privacy information.See omnystudio.com/listener for privacy information.

What transforms a tough-on-crime conservative Christian from Mississippi into a powerful advocate for drug policy reform? For Christina Dent, it was her experience as a foster mom. That launched her on a path to found End It For Good, an organization fighting to revolutionize America's approach to drugs. From sharing her personal story to working with lawmakers, Christina challenges us to question our assumptions about drugs and addiction and imagine a different path forward. To learn more about Christina’s story and how to get involved, check out her book, Curious: A Foster Mom's Discovery of an Unexpected Solution to Drugs and Addiction, and visit enditforgood.com Follow When it Clicked wherever you get your podcasts, or listen ad-free on Amazon Music with your Prime Membership. Stay up to date with us on Twitter, Facebook and Instagram at @LemonadaMedia. Want to become a Lemonada superfan? Join us at joinsubtext.com/lemonadasuperfan. Click this link for a list of current sponsors and discount codes for this and all other Lemonada series: lemonadamedia.com/sponsors. To follow along with a transcript, go to lemonadamedia.com/show/ shortly after the air date. See omnystudio.com/listener for privacy information.See omnystudio.com/listener for privacy information.

In an expected but still stunning escalation, the Trump administration has imposed 25 percent tariffs on goods from Mexico and Canada, citing cross-border flows of fentanyl as justification. The move has sent shockwaves through U.S.-Mexico and North American relations, rattling markets and generating a general outcry. In this episode, Stephanie Brewer, WOLA's director for Mexico, and John Walsh, WOLA's director for drug policy, unpack the political, economic, and security implications of the tariff imposition and an apparent return to failed attempts to stop drug abuse and drug trafficking through brute force. Brewer breaks down how the tariffs and other new hardline policies, like terrorist designations for Mexican criminal groups and fast-tracked extraditions, are reshaping and severely straining the bilateral relationship. Walsh explains why Trump's focus on supply-side crackdowns is doomed to fail, drawing on decades of evidence from past U.S. drug wars. He lays out a harm reduction strategy that would save far more lives. The conversation concludes with an open question: is Donald Trump really interested in a negotiation with Mexico? Or is the goal a permanent state of coercion, which would explain the lack of stated benchmarks for lifting the tariffs? Links: See Brewer and Walsh's February 14, 2025 Q&A on “Tariffs, Fentanyl, and Migration: Updates on U.S.-Mexico Relations after Trump's First Month in Office.“ They covered this territory in a December 5, 2024 podcast episode, shortly after Trump—then the president elect—first signaled his intention to impose tariffs. The December 5 podcast also came with a Q&A: “Trump's Threats of Tariffs as a Response to Migration and the Fentanyl Overdose Crisis.” From the Centers for Disease Control and Prevention: CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths, February 25, 2025 From The Hill: Trump tariffs part of ‘drug war,' not ‘trade war': Commerce secretary, March 4, 2025

Send us a textCannabis Legalization News: The Farm Bill, Federal Policies, and Local DevelopmentsIn this episode of Cannabis Legalization News, Tom discusses various topics surrounding cannabis legislation and industry updates. The main focus is on the Farm Bill, which is expected to be seen before June, according to statements from GT Thompson, the U.S. House Ag Committee Chair. The episode also covers news from across the United States on cannabis legalization efforts, including issues in the House and Senate regarding budget cuts, definitions of hemp, and the impact on SNAP benefits. Tom shares updates from states like Virginia, Ohio, and Texas, discussing the political landscape and potential changes in cannabis laws. Additionally, there's a spotlight on a proposed locally-owned dispensary in Pekin, Illinois, and the potential economic benefits it could bring to the community. The episode also touches on the ramifications of the DOJ's stance on administrative law judges, a study on cannabis' effects on the brain, and various happenings in the cannabis world.00:00 Introduction and Weekly Updates00:31 Farm Bill Discussion02:31 World War 3 and Economic Concerns03:47 Cannabis Legalization and Policy Issues07:01 Trump's Drug Policy and Its Implications10:25 Administrative Law Judges and DEA15:21 Cannabis and Alcohol Consumption Trends28:19 North Carolina's Cannabis Law Controversy32:49 Ohio Traffic Stop and Marijuana Bust34:58 The Importance of a Certificate of Analysis (COA)35:19 Revenue from Legal Weed36:37 HempFest and HempStock36:54 Michigan's Marijuana Tax Dollars37:25 Regulatory Differences Across States37:40 Washington State's Fun Police40:04 Marijuana Research and Brain Studies41:39 Local Cannabis Legalization News44:32 The Future of Cannabis Dispensaries48:05 Hemp Beverages and the Farm Bill52:37 Ohio's Legalization Rollback59:23 Texas Cannabis Legislation01:07:47 Growing Cannabis: Challenges and Opportunities01:09:19 Conclusion and Final ThoughtsSupport the show

An Eastern Conference contender will be without a key contributor after a positive drug test. Correspondent Gethin Coolbaugh reports.

Another major backdown by the New Democrats on their drug policy. George Abbott finally makes it to the treaty commission. New Democrats appointed the former BC Liberal cabinet minister Wednesday. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Good Morning Liberty, hosts Chuck and Nathaniel Paul Thurston dive into various topics, including tariffs announced by Trump on Mexico, Canada, and China, the inaugural segment of Dumb Bleep of the Month, and discussions about trust, political grifters, and controversial statements. They also critique Bill Burr's comments on California wildfires, a lefty bishop's political prayer, and Senate hearings involving RFK Jr. Additionally, the episode covers issues related to SSRIs, DEI, and societal trust, all while maintaining a humorous and critical tone. (02:57) Tariffs and Economic Implications (06:56) Libertarian Perspective on Drug Policy (07:40) Debate on Tariffs and Trade (10:43) Trump's Negotiation Tactics (17:20) Dumb Bleep of the Month Voting Process (18:51) Trump's Controversial Tweet (21:47) MAGA Grifters Feud (27:19) MAGA Grifters and Tariff Hypocrisy (28:00) Bill Burr on California Wildfires (33:19) National Prayer and Transgender Children (36:43) RFK Hearing Highlights (37:21) Debating Antidepressants and Mental Health (49:13) Trust in Society and DEI Concerns (53:01) Dumb Bleep of January Winner   Links:   https://gml.bio.link/   Watch GML  on Youtube:   https://bit.ly/3UwsRiv   Check out Martens Minute!   https://martensminute.podbean.com/   Follow Josh Martens on X:   https://twitter.com/joshmartens13   Join the private discord & chat during the show!   joingml.com   Bank on Yourself bankonyourself.com/gml   Get FACTOR Today! FACTORMEALS.com/gml50   Good Morning Liberty is sponsored by BetterHelp! Rediscover your curiosity today by visiting Betterhelp.com/GML (Get 10% off your first month)     Protect your privacy and unlock the full potential of your streaming services with ExpressVPN. Get 3 more months absolutely FREE by using our link EXPRESSVPN.com/GML  

Don't Skip This Episode! A Former DEA Special Agent Exposes Fentanyl's Role in America's Ongoing Drug Crisis. In this powerful and timely episode of On The Homefront with Jeff Dudan, Jeff sits down with Brian Townsend, a former DEA agent with 28 years of law enforcement experience, including 23 years at the DEA. Together, they uncover the harsh realities of America's growing fentanyl crisis, discuss the staggering statistic that 70% of drugs in the U.S. are contaminated with fentanyl, and explore the life-or-death consequences of this epidemic. Brian shares insights from his career and highlights actionable ways to reduce demand, protect our communities, and educate young people. From the drug trade's deadly economic dynamics to life-saving tools like Narcan, this episode is a must-watch for anyone wanting to understand the depth of this crisis and how we can fight back. Key Topics Covered: Why fentanyl has changed the drug landscape forever How just 2 milligrams of fentanyl can kill The role of cartels and corruption in drug trafficking The need for Narcan in every home Solutions to reduce drug demand and protect the next generation

Don't Skip This Episode! A Former DEA Special Agent Exposes Fentanyl's Role in America's Ongoing Drug Crisis. In this powerful and timely episode of On The Homefront with Jeff Dudan, Jeff sits down with Brian Townsend, a former DEA agent with 28 years of law enforcement experience, including 23 years at the DEA. Together, they uncover the harsh realities of America's growing fentanyl crisis, discuss the staggering statistic that 70% of drugs in the U.S. are contaminated with fentanyl, and explore the life-or-death consequences of this epidemic. Brian shares insights from his career and highlights actionable ways to reduce demand, protect our communities, and educate young people. From the drug trade's deadly economic dynamics to life-saving tools like Narcan, this episode is a must-watch for anyone wanting to understand the depth of this crisis and how we can fight back. Key Topics Covered: Why fentanyl has changed the drug landscape forever How just 2 milligrams of fentanyl can kill The role of cartels and corruption in drug trafficking The need for Narcan in every home Solutions to reduce drug demand and protect the next generation

Egal zu welchem Anlass, in Deutschland wird gerne getrunken. Obwohl der Konsum seit Jahren langsam sinkt, liegen wir im internationalen Vergleich immer noch weit vorn. Schätzungen gehen davon aus, dass jährlich mehr als 40.000 Menschen in Deutschland an den Folgen ihres Alkoholkonsums vorzeitig sterben. Und dennoch gilt Alkoholtrinken immer noch als normal. Warum können - oder wollen - wir nicht auf diese Droge verzichten? Es nur mit dem Rausch, mit der kleinen Flucht aus dem Alltag zu erklären, wäre zu einfach.  Autorin Yasmin Appelhans ist dem Alkoholkonsum wissenschaftlich auf den Grund gegangen und hat dafür auch in der Evolutionsgeschichte gewühlt. Im Gespräch mit Host Lucie Kluth erzählt sie von ihren spannenden Erkenntnissen - unter anderem, warum unser Körper Alkohol relativ gut verarbeiten kann, was die forschungsrelevante "Drunken Monkey Hypothesis" damit zu tun hat und warum gerade Soziale Medien mitverantwortlich dafür sind, dass viele junge Menschen ihren Alkoholkonsum hinterfragen. DIE HINTERGRUNDINFORMATIONEN 1. Dudley R. Evolutionary Origins of Human Alcoholism in Primate Frugivory. The Quarterly Review of Biology. 2000;75(1): 3–15. https://doi.org/10.1086/393255. 2. Carrigan MA, Uryasev O, Frye CB, Eckman BL, Myers CR, Hurley TD, et al. Hominids adapted to metabolize ethanol long before human-directed fermentation. Proceedings of the National Academy of Sciences. 2015;112(2): 458–463. https://doi.org/10.1073/pnas.1404167111. 3. Bowland AC, Melin AD, Hosken DJ, Hockings KJ, Carrigan MA. The evolutionary ecology of ethanol. Trends in Ecology & Evolution. 2024;0(0). https://doi.org/10.1016/j.tree.2024.09.005. 4. Dudley R, Maro A. Human Evolution and Dietary Ethanol. Nutrients. 2021;13(7): 2419. https://doi.org/10.3390/nu13072419. 5. Dashko S, Zhou N, Compagno C, Piškur J. Why, when, and how did yeast evolve alcoholic fermentation? Fems Yeast Research. 2014;14(6): 826–832. https://doi.org/10.1111/1567-1364.12161. 6. Milan NF, Kacsoh BZ, Schlenke TA. Alcohol Consumption as Self-Medication against Blood-Borne Parasites in the Fruit Fly. Current Biology. 2012;22(6): 488–493. https://doi.org/10.1016/j.cub.2012.01.045. 7. Heinz A, Daedelow LS. Alkohol als Kulturgut – eine historisch-anthropologische und therapeutische Perspektive auf Alkoholkonsum und seine soziale Rolle in westlichen Gesellschaften. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2021;64(6): 646–651. https://doi.org/10.1007/s00103-021-03327-8. 8. Cooke R. The Palgrave handbook of psychological perspectives on alcohol consumption. Cham, Switzerland: Springer; 2021. 9. Alkoholkonsum in Deutschland: https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/a/alkohol.html [Accessed 9th December 2024]. 10. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010;376(9752): 1558–1565. https://doi.org/10.1016/S0140-6736(10)61462-6. 11. Mamluk L, Edwards HB, Savović J, Leach V, Jones T, Moore THM, et al. Low alcohol consumption and pregnancy and childhood outcomes: time to change guidelines indicating apparently ‘safe' levels of alcohol during pregnancy? A systematic review and meta-analyses. BMJ Open. 2017;7(7): e015410. https://doi.org/10.1136/bmjopen-2016-015410. 12. Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. The Lancet. 2019;393(10190): 2493–2502. https://doi.org/10.1016/S0140-6736(18)32744-2. 13. Kilian C, Manthey J, Rehm J, Kraus L. Alkoholpolitik in Deutschland: Verpasste Chancen zur Senkung der Krankheitslast. SUCHT. 2023;69(4): 163–171. https://doi.org/10.1024/0939-5911/a000823. 14. Binder A, Kilian C, Hanke S, Banabak M, Berkenhoff C, Petersen KU, et al. Stigma and self-stigma among women within the context of the german “zero alcohol during pregnancy” recommendation: A qualitative analysis of online forums and blogs. International Journal of Drug Policy. 2024;124: 104331. https://doi.org/10.1016/j.drugpo.2024.104331. 15. Stockwell T, Zhao J, Clay J, Levesque C, Sanger N, Sherk A, et al. Why Do Only Some Cohort Studies Find Health Benefits From Low-Volume Alcohol Use? A Systematic Review and Meta-Analysis of Study Characteristics That May Bias Mortality Risk Estimates. Journal of Studies on Alcohol and Drugs. 2024;85(4): 441–452. https://doi.org/10.15288/jsad.23-00283. 16. Cook M, Critchlow N, O'Donnell R, MacLean S. Alcohol's contribution to climate change and other environmental degradation: a call for research. Health Promotion International. 2024;39(1): daae004. https://doi.org/10.1093/heapro/daae004. 17. 3.7 Genetik der Alkoholabhängigkeit.. 2011th ed. Alkohol und Tabak. Thieme Verlag; 2011. https://doi.org/10.1055/b-0034-40723. [Accessed 21st December 2024]. 18. Hakulinen C, Elovainio M, Batty GD, Virtanen M, Kivimäki M, Jokela M. Personality and Alcohol Consumption: Pooled Analysis of 72,949 Adults from Eight Cohort Studies. Drug and alcohol dependence. 2015;151: 110–114. https://doi.org/10.1016/j.drugalcdep.2015.03.008. 19. Heinz A, Gül Halil M, Gutwinski S, Beck A, Liu S. ICD-11: Änderungen der diagnostischen Kriterien der Substanzabhängigkeit. Der Nervenarzt. 2022;93(1): 51–58. https://doi.org/10.1007/s00115-021-01071-7. 20. Alkoholberatung: Alkohol? Kenn dein Limit. https://www.kenn-dein-limit.de/alkoholberatung/ [Accessed 21st December 2024].

Season 6 begins with a discussion with Regina LaBelle of the O'Neill Institute for National and Global Health at the Georgetown University Law Center. A policy expert with significant experience in practice at the municipal and federal levels, we talk about potential changes in the new administration.

Egal zu welchem Anlass, in Deutschland wird gerne getrunken. Obwohl der Konsum seit Jahren langsam sinkt, liegen wir im internationalen Vergleich immer noch weit vorn. Schätzungen gehen davon aus, dass jährlich mehr als 40.000 Menschen in Deutschland an den Folgen ihres Alkoholkonsums vorzeitig sterben. Und dennoch gilt Alkoholtrinken immer noch als normal. Warum können - oder wollen - wir nicht auf diese Droge verzichten? Es nur mit dem Rausch, mit der kleinen Flucht aus dem Alltag zu erklären, wäre zu einfach.  Autorin Yasmin Appelhans ist dem Alkoholkonsum wissenschaftlich auf den Grund gegangen und hat dafür auch in der Evolutionsgeschichte gewühlt. Im Gespräch mit Host Lucie Kluth erzählt sie von ihren spannenden Erkenntnissen - unter anderem, warum unser Körper Alkohol relativ gut verarbeiten kann, was die forschungsrelevante "Drunken Monkey Hypothesis" damit zu tun hat und warum gerade Soziale Medien mitverantwortlich dafür sind, dass viele junge Menschen ihren Alkoholkonsum hinterfragen. DIE HINTERGRUNDINFORMATIONEN 1. Dudley R. Evolutionary Origins of Human Alcoholism in Primate Frugivory. The Quarterly Review of Biology. 2000;75(1): 3–15. https://doi.org/10.1086/393255. 2. Carrigan MA, Uryasev O, Frye CB, Eckman BL, Myers CR, Hurley TD, et al. Hominids adapted to metabolize ethanol long before human-directed fermentation. Proceedings of the National Academy of Sciences. 2015;112(2): 458–463. https://doi.org/10.1073/pnas.1404167111. 3. Bowland AC, Melin AD, Hosken DJ, Hockings KJ, Carrigan MA. The evolutionary ecology of ethanol. Trends in Ecology & Evolution. 2024;0(0). https://doi.org/10.1016/j.tree.2024.09.005. 4. Dudley R, Maro A. Human Evolution and Dietary Ethanol. Nutrients. 2021;13(7): 2419. https://doi.org/10.3390/nu13072419. 5. Dashko S, Zhou N, Compagno C, Piškur J. Why, when, and how did yeast evolve alcoholic fermentation? Fems Yeast Research. 2014;14(6): 826–832. https://doi.org/10.1111/1567-1364.12161. 6. Milan NF, Kacsoh BZ, Schlenke TA. Alcohol Consumption as Self-Medication against Blood-Borne Parasites in the Fruit Fly. Current Biology. 2012;22(6): 488–493. https://doi.org/10.1016/j.cub.2012.01.045. 7. Heinz A, Daedelow LS. Alkohol als Kulturgut – eine historisch-anthropologische und therapeutische Perspektive auf Alkoholkonsum und seine soziale Rolle in westlichen Gesellschaften. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2021;64(6): 646–651. https://doi.org/10.1007/s00103-021-03327-8. 8. Cooke R. The Palgrave handbook of psychological perspectives on alcohol consumption. Cham, Switzerland: Springer; 2021. 9. Alkoholkonsum in Deutschland: https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/a/alkohol.html [Accessed 9th December 2024]. 10. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010;376(9752): 1558–1565. https://doi.org/10.1016/S0140-6736(10)61462-6. 11. Mamluk L, Edwards HB, Savović J, Leach V, Jones T, Moore THM, et al. Low alcohol consumption and pregnancy and childhood outcomes: time to change guidelines indicating apparently ‘safe' levels of alcohol during pregnancy? A systematic review and meta-analyses. BMJ Open. 2017;7(7): e015410. https://doi.org/10.1136/bmjopen-2016-015410. 12. Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. The Lancet. 2019;393(10190): 2493–2502. https://doi.org/10.1016/S0140-6736(18)32744-2. 13. Kilian C, Manthey J, Rehm J, Kraus L. Alkoholpolitik in Deutschland: Verpasste Chancen zur Senkung der Krankheitslast. SUCHT. 2023;69(4): 163–171. https://doi.org/10.1024/0939-5911/a000823. 14. Binder A, Kilian C, Hanke S, Banabak M, Berkenhoff C, Petersen KU, et al. Stigma and self-stigma among women within the context of the german “zero alcohol during pregnancy” recommendation: A qualitative analysis of online forums and blogs. International Journal of Drug Policy. 2024;124: 104331. https://doi.org/10.1016/j.drugpo.2024.104331. 15. Stockwell T, Zhao J, Clay J, Levesque C, Sanger N, Sherk A, et al. Why Do Only Some Cohort Studies Find Health Benefits From Low-Volume Alcohol Use? A Systematic Review and Meta-Analysis of Study Characteristics That May Bias Mortality Risk Estimates. Journal of Studies on Alcohol and Drugs. 2024;85(4): 441–452. https://doi.org/10.15288/jsad.23-00283. 16. Cook M, Critchlow N, O'Donnell R, MacLean S. Alcohol's contribution to climate change and other environmental degradation: a call for research. Health Promotion International. 2024;39(1): daae004. https://doi.org/10.1093/heapro/daae004. 17. 3.7 Genetik der Alkoholabhängigkeit.. 2011th ed. Alkohol und Tabak. Thieme Verlag; 2011. https://doi.org/10.1055/b-0034-40723. [Accessed 21st December 2024]. 18. Hakulinen C, Elovainio M, Batty GD, Virtanen M, Kivimäki M, Jokela M. Personality and Alcohol Consumption: Pooled Analysis of 72,949 Adults from Eight Cohort Studies. Drug and alcohol dependence. 2015;151: 110–114. https://doi.org/10.1016/j.drugalcdep.2015.03.008. 19. Heinz A, Gül Halil M, Gutwinski S, Beck A, Liu S. ICD-11: Änderungen der diagnostischen Kriterien der Substanzabhängigkeit. Der Nervenarzt. 2022;93(1): 51–58. https://doi.org/10.1007/s00115-021-01071-7. 20. Alkoholberatung: Alkohol? Kenn dein Limit. https://www.kenn-dein-limit.de/alkoholberatung/ [Accessed 21st December 2024].

Can relentless advocacy truly shape the future of marijuana legislation? Join us on the Drug Report podcast as we explore the recent triumph in New Hampshire, where the unwavering efforts of advocates have led Governor Kelly Ayotte to promise a veto on any future marijuana legalization attempts. This victory shines a light on the power of persistence in the ever-evolving landscape of drug policy. As we navigate through these pivotal changes, we're also dissecting the challenges faced by the marijuana industry in New York, revealing how initial promises of social equity have not been fulfilled, leaving many equity applicants in financial distress. Kevin Sabet's op-ed adds a critical perspective to our discussion, emphasizing the widening gap between wealthy investors and disenfranchised communities.Our conversation takes a crucial turn as we tackle issues surrounding medical marijuana prescriptions, drawing comparisons to the opioid crisis of the 1990s. How can we ensure patient safety when a small group of doctors dominates the recommendation landscape? We're also looking at the ongoing efforts in Florida to legalize marijuana and the strategic legislative initiatives being considered by the new Congress. Randy's resolution serves as a cornerstone in raising awareness about the risks of high-potency THC, reflecting a broader strategic approach to drug policy reform and patient protection.Federal marijuana legalization remains a hot topic, with the complexities of state and federal enforcement at the forefront. We address the urgent need for Congress to empower the DOJ in regulating marijuana sales near schools, while also examining the emerging debate around Delta 8, especially as companies like DoorDash enter the market. The unexpected halt in the marijuana rescheduling process due to an industry-filed motion has opened the door for broader scrutiny and discussion. President Trump's ambiguous remarks about the Safe Banking Act add another layer of uncertainty, as we acknowledge the collaborative efforts of advocates striving to navigate these challenging waters. Join us as we break down these pressing issues and stay informed on the latest developments.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Gubernatorial candidate Toni Atkins discusses her historic political journey and vision for California, and Brian Cuban shares his recovery story and new book 'The Body Brokers'. Toni AtkinsToni Atkins (toniatkins.org)Brian CubanThe Body Brokers by Brian Cuban (bookcandystudios.com)briancuban.com Check out other MSW Media podcastshttps://mswmedia.com/shows/Subscribe for free to MuellerSheWrote on Substackhttps://muellershewrote.substack.comFollow AG and Dana on Social MediaDr. Allison Gill Substack|Muellershewrote, Twitter|@MuellerSheWrote, Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, BlueSky|@muellershewroteDana GoldbergTwitter|@DGComedy, IG|dgcomedy, facebook|dgcomedy, IG|dgcomedy, danagoldberg.com, BlueSky|@dgcomedyHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?Supercasthttps://dailybeans.supercast.com/Patreon https://patreon.com/thedailybeansOr subscribe on Apple Podcasts with our affiliate linkThe Daily Beans on Apple Podcasts

Stacey Forrester, head of harm reduction at British Columbia's Bass Coast Festival and founder of Good Night Out Vancouver, joins us for a frank and fun chat about something we don't talk about enough in the rave scene: drugs and drug safety. We learn about harm reduction and community, how they use diamonds for drug testing, the best way to talk someone down, what chemicals to look out for, how Western Canada became the forefront of North American drug policy and how a nurse-ballerina turned into your favorite rave fairy godmother, among other things. Taped live at Bass Coast Festival in Merritt BC! Hosted by Vivian Host (aka DJ Star Eyes). For more info and extras, visit Ravetothegrave.org or Instagram @ravetothe.grave.

In this episode of the Closet Disco Queen Podcast, Queenie and TT explore various themes surrounding adult-use cannabis, including the failures of the war on drugs, the differences between CBD and THC, and the role of cannabis in pain management. They also share personal anecdotes about holiday traditions and family gatherings, creating a light-hearted yet informative atmosphere for listeners.Welcome to the Closet Disco Queen Pot-Cast, a comedy podcast with music and pop culture references that keeps you laughing and engaged. Join our hosts, Queenie & TT as they share humorous anecdotes about daily life, offering women's perspectives on lifestyle and wellness. We dive into funny cannabis conversations and stories, creating an entertaining space where nothing is off-limits. Each episode features entertaining discussions on pop culture trends, as we discuss music, culture, and cannabis in a light-hearted and inclusive manner. Tune in for a delightful blend of humor, insight, and relatable stories that celebrate life's quirks and pleasures. Our Closet Disco Queen Pot-Cast deals with legal adult cannabis use and is intended for entertainment purposes only for those 21 and older Visit our Closet Disco Queen Pot-Cast merch store!Find us on Facebook and Green Coast RadioSound from Zapsplat.com, https://quicksounds.com, 101soundboards.com #ToneTransfer

On November 25, President-Elect Donald Trump announced via social media that he would impose a 25 percent tariff on all imports from Mexico and Canada unless migration and fentanyl trafficking ceased entirely. The announcement caused widespread alarm, spurring a flurry of responses and an unclear conversation between Trump and Mexican President Claudia Sheinbaum. The event was instructive about what we might expect after Trump assumes the presidency in January, observe WOLA Director for Mexico Stephanie Brewer and Director for Drug Policy John Walsh. Brewer explained the "tariff threat" incident, how it plays into the political agendas of both Trump and Sheinbaum, and the danger of doing serious damage to a multifaceted, interdependent bilateral relationship. Host Adam Isacson, who covers border and migration policy at WOLA, joined the discussion to point out that Trump seeks to bully Mexico into carrying out a crackdown on migration that has, in fact, already been underway for some time with serious human rights implications. Walsh observed that demands on Mexico to crack down on fentanyl threaten a reversion to supply-side, prohibitionist approaches to a complex drug problem that not only haven't worked over the past 50 years, but may in fact have ceded much control to armed and criminal groups. The U.S.-Mexico border, and the bilateral relationship, may be marked by these episodes of threat and bluster for much of the next few years. Weathering this period will require civil society in both the United States and Mexico to play an aggressive role, demanding "steadiness, focus on facts, keeping things grounded in reality," and never losing sight of what better migration and drug policies would look like.

Kevin Kirby, managing director at Health Management Associates, gives a closer look at the evolution of Medicare's drug coverage and the policies that have transformed patient access and affordability. From Clinton era ideas, to the launch of the Medicare Modernization Act and then the Affordable Care Act, Kevin has advised clients as these significant milestones have shaped and reshaped Medicare's drug benefits. He discusses the implications of the Inflation Reduction Act, raising important questions about sustainability and cost control. The episode will explore how these pivotal policies will impact access to treatment and the sustainability of Medicare in a rapidly changing healthcare landscape. 

In this one we dive into the complexities surrounding the concept of cartels, particularly in the context of the drug trade. Do drug cartels in Latin America exist? In this interview we discuss how misconceptions about cartels have been shaped by narratives in media and government, leading to a distorted understanding of their economic realities and the implications of militarization in regions affected by drug violence. With me to unpack this idea, is journalist, professor, and author of “Cartels Do Not Exist, Narcotrafficking in US and Mexican Culture,” Oswaldo Zavala. Chapters (00:00) - Understanding the Complexity of Ideas ~ Intro Essay (05:40) - The Nature of Cartels: Definitions and Misconceptions (10:03) - The Narrative Device of Cartels (19:49) - The Economic Reality of Drug Organizations (29:48) - The Interplay of Violence and Militarization (40:15) - Challenging the Official Narrative on Drug Trafficking (43:39) - The Role of Media in Shaping Perceptions (46:52) - Violence, Assassinations, and the Drug Trade (51:08) - Historical Context of Drug Organizations and Violence (55:22) - The Impact of Militarization on Violence (01:01:04) - Extractive Industries and the Drug War (01:04:15) - Decriminalization and Its Implications (01:09:21) - Rethinking National Security and Drug Policy

Howie and Harlan are joined by Rahul Rajkumar, founder and CEO of Accompany Health, which provides a team of providers for patients who are on both Medicare and Medicaid. Harlan reflects on a visit to China and the healthcare ramifications of proposed legislation that would force U.S. biotech companies to cut ties with some Chinese partners. Howie provides an update on healthcare-related measures on state ballots in last week's election.  Links: China and the Biosecure Act “Congress takes up a series of bills targeting China, from drones to drugs” “U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners” Accompany Health Accompany Health Medicare: Dual-Eligibles Centers for Medicare & Medicaid Services: Dual Eligible Special Needs Plans “Medicaid Enrollees by Enrollment Group” “Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys” “10 Reasons Why Medicare Advantage Enrollment is Growing and Why It Matters” Healthcare on the Ballot “7 states vote to protect abortion rights, while efforts to expand access in Florida, Nebraska and South Dakota fail” “Marijuana and Drug Policy on the Ballot” “Massachusetts voters reject proposal to legalize certain psychedelic drugs” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

John Stonestreet and Maria Baer break down the results of this week's election from the presidential race to state ballot initiatives. Recommendations Pray for our officials through the Psalms Hillsdale College and Liberty University Segment 1 - 2024 Election How to Live as Christians After the Election | John Stonestreet at Liberty University Colson Fellows Program WORLD: We're faced with a crisis by John Stonestreet Segment 2 - State Initiatives Live Action: Abortion on the ballot: Where voters protected preborn children, and where they didn't Breakpoint: Voting: Lesser of Two Evils vs. Lessening Evil  First Things: The Way Forward After Dobbs by Ryan T. Anderson Segment 3 - Impact of the Election and More State Initiatives CNN: Antisemitic attacks on Israeli soccer fans bring shame on Amsterdam, mayor says NYT: Marijuana and Drug Policy on the Ballot California Approves Tough-on-Crime Initiative Anthony Bradley on X West Virginia voters approve constitutional ban on physician-assisted suicide __________ Reserve your spot for the next Lighthouse Voices event: A New Sexual Revolution with Os Guinness at colsoncenter.org/lighthouse.  Register for the Colson Fellows Church Affiliate Informational Webinar on November 14 at colsoncenter.org/church. 

ASHP's Senior education director, Cindy von Heeringen is joined by Dr. Alex Infante, Clinical Assistant Professor at Texas A&M University  and Dr. Jennie Jarrett, Director of Science and Drug Policy at the American Medical Association as they discuss their upcoming Midyear session that focuses on the ability of pharmacists to use available resources and strategies to positively impact patient care by overcoming barriers in the implementation and utilization of harm reduction services. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Discover the complexities of today's drug policy landscape with insights from around the globe. We promise an enlightening journey as Kevin Sabat and I unpack the highlights from the recent Lisbon Addictions Conference. We bring you the latest updates and debates on harm reduction versus legalization, spotlighting data-driven discussions from regions like Oregon and British Columbia. As we shift focus to the United States, uncover the stories behind various drug policy ballot measures, including marijuana legalization efforts in Florida and the Dakotas. The challenges New York faces in its legalization journey serve as a cautionary tale, and we even touch on an intriguing psychedelics measure in Massachusetts, hinting at the evolving dynamics in drug policy.In a special segment, Kevin joins me to highlight the importance of staying informed through resources like newsletters from learnaboutsamorg and thedrugreportorg. We emphasize the value of evidence-based policies and encourage robust discussions among our listeners. Make sure to engage with us by subscribing to these newsletters for the latest updates and leave a review to help amplify the conversation. Tune in for a comprehensive understanding of the forces shaping the future of drug policy around the world.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

There are a lot of reasons, including heavy regulations, high taxes, and competition from illegal weed shops. Most operators are losing money and waiting for Washington to get out of the way. In the meantime, it's not that easy being green. (Part two of a four-part series.) SOURCES:Jon Caulkins, professor of operations research and public policy at Carnegie Mellon University.Adam Goers, senior vice president of The Cannabist Company and chairperson of the Coalition for Cannabis Scheduling Reform.Precious Osagie-Erese, founder and C.E.O. of Precious Canna Co.Nikesh Patel, C.E.O. of Mammoth Distribution.Nikesh Patel, director of the San Francisco Office of Cannabis.Tom Standage, deputy editor of The Economist. RESOURCES:"Most Americans Favor Legalizing Marijuana for Medical, Recreational Use," (Pew Research Center, 2024)."Whitney Economics U.S. Legal Cannabis Forecast - 2024 - 2035," by Beau Whitney (Whitney Economics, 2024)."Beer Sellers Use a Loophole to Break Into Weed Drinks Market," by Redd Brown (Bloomberg, 2024)."Cannabis Producer Seeks Boston Beer Merger," by Lauren Thomas (The Wall Street Journal, 2024)."California's 'Apple Store of Weed' Declares Bankruptcy With $410M in Debt," by Lester Black (SFGate, 2024)."Is the State Democratic Chair Influencing Who Can Sell Legal Weed in this N.J. City?" by Jelani Gibson (NJ.com, 2023)."When Prohibition Works: Comparing Fireworks and Cannabis Regulations, Markets, and Harms," by Jonathan P. Caulkins and Kristina Vaia Reimer (International Journal of Drug Policy, 2023)."Did Minnesota Accidentally Legalize Weed?" by Paul Demko (Politico, 2022). EXTRAS:"Is America Switching From Booze to Weed?" by Freakonomics Radio (2024)."The Economics of Sports Gambling," by Freakonomics Radio (2019).

The opioid crisis is still happening, unfortunately. Email: EverythingIsPublicHealth@gmail.com    Patreon: https://www.patreon.com/everythingispublichealth  Bluesky Social: @everythingisPHMastodon: @everythingispublichealth  Instagram and Threads: Everything is Public Health  Photo Credit: Photo by Hal Gatewood on UnsplashReferences: Empire of PainThe Secret History of the Sackler DynastyBy Patrick Radden KeefeLast Week Tonight did FOUR parts on thishttps://www.youtube.com/watch?v=5pdPrQFjo2ohttps://www.youtube.com/watch?v=-qCKR6wy94Uhttps://www.youtube.com/watch?v=uaCaIhfETsMhttps://www.youtube.com/watch?v=Io0yuH1CiA0 https://www.npr.org/2023/12/28/1220881380/overdose-fentanyl-drugs-addictionhttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790432?te=1&nl=the-morning&emc=edit_nn_20240903https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#Fig2https://www.cdc.gov/museum/pdf/cdcm-pha-stem-uncovering-the-opioid-epidemic-lesson.pdfhttps://www.politico.com/story/2018/08/28/how-the-opioid-crackdown-is-backfiring-752183https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htmhttps://www.samhsa.gov/find-help/harm-reductionhttps://www.npr.org/2024/09/30/nx-s1-5124997/fentanyl-overdose-opioid-btmps-drug-cartel-xylazine-tranq-mexico-chinahttps://www.npr.org/2024/09/18/nx-s1-5107417/overdose-fatal-fentanyl-death-opioidSupport the show

With the popularity of recreational and medical marijuana how is a company to enforce a drug policy? Just finding employees that don't use marijuana is a struggle but ignoring the possible risks and harm drug use can have in the workplace is not the answer any of us can afford to practice. Doug Oldham from Barnes and Thornburg in Columbus, Ohio joins Pandy to discuss how to craft an effective drug policy when considering marijuana in the workplace.

Can marijuana regulation backfire on public health? Join us on the Drug Report podcast as we celebrate International Recovery Day and tackle this provocative question with insights from experts like Michael Botticelli and John Kelly. We'll share highlights from a global webinar focused on the mechanisms and societal support necessary for successful recovery. We'll also respond to Robert Gebeloff's Washington Post column advocating for federal marijuana regulation, raising concerns about big tobacco's potential entry into the marijuana market and the resulting public health issues. Plus, you'll hear a detailed recount of the recent debate on Florida's Amendment 3 for recreational marijuana legalization, shedding light on the ongoing complexities in drug policy reform.Are veterans being misled about marijuana's effects on PTSD? In a crucial segment of this episode, Kevin Sabet and I dismantle the misinformation spreading within veteran communities. Drawing on recent studies, including research from Yale University, we reveal that marijuana may actually worsen PTSD symptoms, contradicting popular belief. We underscore the importance of distributing accurate information to better support our veterans and encourage our listeners to help by leaving a five-star rating and writing a review. Gain valuable insights and join the conversation on drug policy and recovery by tuning in to this thought-provoking and informative episode.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

In this episode of Main Street Matters, Elaine and Jordan speak with Michelle Leopold, a small business owner and activist, about the tragic loss of her son to fentanyl overdose and her subsequent efforts to raise awareness about the dangers of fentanyl and the importance of education. Michelle shares her personal story, the impact of drug policies on small businesses in California, and the challenges faced by business owners due to crime. She emphasizes the need for community engagement, education on drug use, and policy changes to address the ongoing drug crisis. Main Street Matters is part of the Salem Podcast Network. For more visit JobCreatorsNetwork.comSee omnystudio.com/listener for privacy information.

Christina Dent, founder of End It For Good, Author - Curious, shares her journey of understanding addiction and advocating for a new approach to drug policy. She recounts her experience as a foster parent and meeting a mother struggling with addiction, which challenged her preconceived notions. This led her to question the effectiveness of the criminal justice system in addressing drug use and to explore alternative solutions. She discusses the Rat Park experiment and the importance of addressing the underlying reasons for substance use. Christina emphasizes the need for personalized pathways to recovery and a shift away from a one-size-fits-all approach. The illegal drug economy, fueled by drug prohibition, incentivizes crime and violence by providing a financial incentive. Gangs, cartels, and terrorist organizations are primarily funded through the proceeds of the drug trade. Prohibition also leads to the production of unregulated and dangerous drugs, such as fentanyl, which has contributed to the overdose crisis. The current approach to drug policy is reactive and fear-based, and it is important to shift towards a health-centered approach that addresses the root causes of addiction. Regular people can lead the charge for change and create a movement towards policy reform. Connect with me for Coaching, Consulting or to come and speak at George@tattooedpastor.com Buy my book The Uncovery https://www.briteaton.com/The-Uncovery-Book My personal website https://www.georgeawood.com/ Sober Truth Project https://sobertruthproject.org/ https://www.facebook.com/tattooedpastorgw/ https://linktr.ee/tattooedpastor

This podcast episode features Kendra McSweeney and Fritz Pinnow, part of a team investigating a new trend: the emergence of coca cultivation in Central America. McSweeney, a professor of geography at Ohio State University, has research human-environment interactions, cultural and political ecology, conservation and development, resilience, demography, and land use/cover change. Pinnow is a Honduras-based journalist and documentary photographer specializing in illicit economies, violence and development in Central America. Photo credit: Fritz Pinnow McSweeney and colleagues have published an article in the journal Environmental Research Letters examining the recent and growing appearance of coca leaf cultivation in Central America, a crop historically associated with the Andean region. McSweeney and Pinnow discuss the environmental and market conditions driving coca cultivation in Honduras and Guatemala. They note that those attempting coca cultivation in the region have competitive advantages over Colombian growers, such as more favorable growing conditions. They stress that it would be a serious error to respond to this phenomenon with another forced eradication program. Past crop-eradication strategies, which have almost always been uncoordinated with governance, rule of law, basic services, land formalization, or anti-poverty efforts, have failed and in fact ended up encouraging the planting of coca in new areas. The drug trade, McSweeney and Pinnow state, gains much of its power and wealth from the price premium made possible by the coca plant's illegality. The inflated prices make it very difficult to offer viable economic alternatives in poor rural areas. “Current drug policy,” McSweeney says, “systematically undermines any other efforts at rural or urban development in these countries.” “If we've learned anything from supply side drug control in South America, it's that eradicating coca crops and trying to shut down trafficking organizations, and trying to shut down the cartels, and trying to go after the Pablo Escobar's and their successors– it generates a lot of Netflix content, but it doesn't do anything to reduce the amount of drugs that make it into the United States and other countries… What we've seen from these approaches and after 40 years of the drug war and billions of dollars spent to eradicate the cocaine trade is more coca being produced in Colombia than ever before, more places with coca being produced, the price of cocaine is lower than it's been in decades, the quality of the cocaine is the highest it's ever been, and it's easier to get than it ever was before.” To stay engaged with drug war reform, McSweeney and Pinnow recommend connecting with Students for Sensible Drug Policy (SSDP) and The Centre for the Study of Illicit Economies, Violence and Development (CIVAD).

Can a balanced approach to harm reduction and recovery really save lives? Join us in a thought-provoking conversation with Tom Wolf, a member of the Recovery community from San Francisco, offering a raw and unfiltered critique of today's drug policies. We scrutinize Vancouver's harm reduction model and its alarming overdose death rates, while Tom passionately argues for recovery-focused solutions in the face of new proposals advocating "safe" drug-use spaces and other radical drug provisions. This episode sheds light on the crucial need to integrate more sensible harm reduction interventions with prevention, treatment, and recovery initiatives for a more humane and effective drug policy.Dive deep into the broader debate on drug policy strategies as we question advocates' desire to legalize all drugs, scrutinize the opioid crisis, and expose the cultural influence of big corporations on advocacy. With Tom's powerful insights, we explore how recovery voices must lead the way in policymaking. Listen as we highlight real-life advocacy successes from San Francisco and discuss the vital role of individuals in recovery in shaping policies that truly address addiction. This episode is a comprehensive examination of the pressing issues in drug policy, offering a blueprint for a balanced and recovery-centric approach.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can changing bail laws solve the epidemic of drug addiction and mental illness plaguing British Columbia? Join us as Michael Mulligan challenges the status quo, making the case that the province's focus on bail reform is a misstep. Instead, Mulligan argues for a more holistic approach that prioritizes comprehensive treatment resources to tackle the roots of criminal behavior. Through a critical analysis of current policies, we uncover why simply altering the bail system won't lead to a significant reduction in crime or social disorder.In our exploration, we examine a heartbreaking case from Surrey, shedding light on the daunting decisions judges face during bail hearings. The episode delves into the difficult balance between public safety and individual rights when dealing with offenders who have violent histories and mental health issues. We scrutinize the political ramifications of public outrage over repeat offenders and discuss the need for reform in drug treatment policies, stressing the inadequacies of the current system. This conversation is essential for understanding the broader social issues at play and the real challenges in addressing crime through the legal system alone.Lastly, we turn our attention to the complexities of inheritance laws in British Columbia, focusing on a recent contested will case that underscores the importance of fair asset distribution. Highlighting Section 60 of the Wills Estates and Succession Act, we discuss how courts can intervene to ensure just support for spouses or children, even when traditional values clash with modern expectations. This segment offers valuable insights into careful estate planning, illustrating how to prevent legal disputes and ensure that your final wishes are respected and honored. Whether you're interested in legal reform, social justice, or family law, this episode promises to be both enlightening and thought-provoking.Follow this link for a transcript of the show and links to the cases discussed.

Last month, the first psychedelic therapy treatment came before the Food and Drug Administration for a vote. It entailed using MDMA, also known as ecstasy or molly, to treat PTSD.MDMA therapy has looked promising as a treatment for PTSD and other mental health conditions in some studies. But the FDA scientific advisory panel that evaluated this treatment voted overwhelmingly against approving it.Many of the arguments against approval had less to do with MDMA itself than with the methodology of the clinical trials done by Lykos Therapeutics, formerly the Multidisciplinary Association for Psychedelic Studies, or MAPS. The FDA panel was presented with allegations of misconduct and incongruous data, including a letter by trial participant Sarah McNamee.McNamee, who joined the trial for treatment of PTSD, is also a licensed psychotherapist and researcher of trauma and psychotherapy at McGill University in Montreal. She joins guest host Rachel Feltman alongside Dr. Eiko Fried, a methodologist and psychologist at Leiden University in the Netherlands, to discuss the decision.If you or someone you know is struggling with PTSD or other mental health conditions, call 988 for the suicide and crisis lifeline.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Can the profit motive in free markets lead to disastrous outcomes when it comes to addictive substances like marijuana? We explore this vital question with Charles Lehman from the Manhattan Institute, who brings a compelling analysis of the economic and societal impacts of marijuana legalization. Charles discusses the tension between individual rights and community well-being, emphasizing how addiction can significantly distort rational self-interest. We also shine a light on the often-overlooked societal costs, such as increased emergency services and workplace accidents, that accompany marijuana legalization. In our conversation, we unravel the complexities of addiction and the predictable failures of rationality it involves, using the opioid crisis as a striking example. We delve into Mark Kleiman's innovative ideas on marijuana regulation and the challenges of prohibition versus legalization. Political motivations behind marijuana pardons and changing public sentiments towards legal cannabis are also dissected. Tune in for personal reflections on marijuana use and insights from those in recovery, shaping a broader understanding of drug policy and addiction.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Join us as we dissect Vermont's legislative decision to establish an injection site in Burlington, despite Governor Phil Scott's veto. We'll scrutinize the mixed results from British Columbia and other regions to question the efficacy and safety of these facilities. Then, let's debunk the myths around youth marijuana use trends from the Colorado Healthy Kids Survey. We'll expose how changes in data collection methods have created misleading results, urging us to reconsider if our resources could be better spent on prevention, treatment, and recovery initiatives.This episode also dives into the ongoing efforts surrounding marijuana rescheduling, emphasizing the importance of public involvement in shaping drug policy. Stay informed and engaged by visiting learnaboutsam.org and thedrugreport.org for more details and twice-weekly updates. Don't miss this essential conversation that cuts through the noise to propose more effective approaches to today's drug policy challenges.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Jeff discusses drug policy in American with researcher and author Karl Zinsmeister. In addition to background on the drug epidemic and policy responses over the years, they focus on recent moves to relax enforcement of anti-drug laws, even to the extent of legalizing a variety of narcotics, such as what Oregon did only a few […]

Jeff discusses drug policy in American with researcher and author Karl Zinsmeister. In addition to background on the drug epidemic and policy responses over the years, they focus on recent moves to relax enforcement of anti-drug laws, even to the extent of legalizing a variety of narcotics, such as what Oregon did only a few years ago. Instead of solving the crime and human degradation these progressive policies sought to address, they instead led to massive increases in overdose deaths, more crime, and other problems.Read Karl's book: https://a.co/d/03zBw1YRead Karl's RCP article: https://tinyurl.com/bde2p5x9Host: Jeff SikkengaExecutive Producer: Greg McBrayerProducer: Jeremy GyptonSubscribe: https://linktr.ee/theamericanidea #drugpolicy #legalization

This month, President Biden announced the Justice Department is planning a shift in the federal approach to marijuana, reclassifying it from a Schedule I drug to Schedule III. This would put it in the same category as Tylenol and ketamine. It would classify it as a drug that has the potential for abuse but has medicinal benefits. Amna Nawaz discussed more with Natalie Fertig of Politico. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

In this episode, Joe interviews two members of The Daschle Group: Founder and CEO, Senator Tom Daschle; and Public Policy Advisor, Charlie Panfil. As Senator Daschle served in the House of Representatives for eight years (starting in 1978) and the Senate for 21, he was deep in the War on Drugs at its peak, and thankfully, as seen with so many of his constituents in recent years, the data and personal stories of so many healed people has broken through the propaganda and made him a strong advocate for psychedelic-assisted therapy. While minds are changing and progress is happening before our eyes (the majority of substances the FDA is currently researching for psychiatric indications contain some form of psychedelic ingredient), government bureaucracy, a severe lack of communication between the FDA and DEA, and decades of lies are still massive roadblocks. How do we address all of this while advancing research? They discuss: The need to develop a partnership between the public and private sectors, mostly for the cost of treatments The DEA's place in all of this: If they're essentially a law enforcement agency, why are they involved in the safety and efficacy of medical treatments? The STATES Act, the Breakthrough Therapies Act, and how they can affect research Why we need to move past relying on opioids, and instead, embrace a science-based drug policy and more! For links, head to the show notes page. 

Drug policy feels very unsettled right now. The war on drugs was a failure. But so far, the war on the war on drugs hasn't entirely been a success, either.Take Oregon. In 2020, it became the first state in the nation to decriminalize hard drugs. It was a paradigm shift — treating drug-users as patients rather than criminals — and advocates hoped it would be a model for the nation. But then there was a surge in overdoses and public backlash over open-air drug use. And last month, Oregon's governor signed a law restoring criminal penalties for drug possession, ending that short-lived experiment.Other states and cities have also tipped toward backlash. And there are a lot of concerns about how cannabis legalization and commercialization is working out around the country. So what did the supporters of these measures fail to foresee? And where do we go from here?Keith Humphreys is a professor of psychiatry at Stanford University who specializes in addiction and its treatment. He also served as a senior policy adviser in the Obama administration. I asked him to walk me through why Oregon's policy didn't work out; what policymakers sometimes misunderstand about addiction; the gap between “elite” drug cultures and how drugs are actually consumed by most people; and what better drug policies might look like.Mentioned:Oregon Health Authority dataBook Recommendations:Drugs and Drug Policy by Mark A.R. Kleiman, Jonathan P. Caulkins and Angela HawkenDopamine Nation by Anna LembkeConfessions of an English Opium Eater by Thomas De QuinceyThoughts? Guest suggestions? Email us at ezrakleinshow@nytimes.com.You can find transcripts (posted midday) and more episodes of “The Ezra Klein Show” at nytimes.com/ezra-klein-podcast. Book recommendations from all our guests are listed at https://www.nytimes.com/article/ezra-klein-show-book-recs.This episode of “The Ezra Klein Show” was produced by Annie Galvin. Fact-checking by Michelle Harris, with Kate Sinclair and Mary Marge Locker. Our senior engineer is Jeff Geld, with additional mixing by Aman Sahota and Efim Shapiro. Our senior editor is Claire Gordon. The show's production team also includes Rollin Hu and Kristin Lin. Original music by Isaac Jones. Audience strategy by Kristina Samulewski and Shannon Busta. The executive producer of New York Times Opinion Audio is Annie-Rose Strasser. Special thanks to Sonia Herrero.

For the last 50 years, the government has classified Marijuana as a schedule one drug.Last Tuesday, Attorney General Merrick Garland did initiate the process to reclassify marijuana as a schedule three drug. Those substances are considered by the Drug Enforcement Agency to have moderate to low potential for physical and psychological dependence.This recommendation does not make marijuana legal at the federal level. But for the first time, the government is acknowledging marijuana's potential medical benefits.We discuss what this move means for marijuana research, and drug policy more broadly.Want to support 1A? Give to your local public radio station and subscribe to this podcast. Have questions? Connect with us. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In 2020 Oregon voters overwhelmingly passed a measure that decriminalized drug use. Since the law went into effect three years ago, homelessness in the state has increased, the rate of overdose deaths has risen sharply and the support for decriminalization has plummeted. Now, Oregon legislators on both sides of the aisle are considering overturning the measure, reinstating a more “law and order” approach to addiction. “Drugs are a symptom of what's going on,” says Maia Szalavitz, contributing opinion writer at the New York Times who covers addiction and public policy. “Drugs are not the primary cause of what happened.” Szalavitz joins Diane on the latest episode of On My Mind to talk about the fight over decriminalizing drugs in Oregon – and what it means for the rest of the country.

Over the past decade, Fentanyl, a cheap, hyper-potent, and synthetic opiate has accelerated the opioid pandemic already ravaging the country. Abdul reflects on the way that our atomized, lonely communities left us vulnerable to opioid addiction and fentanyl and sits down with Dr. Rahul Gupta, director of National Drug Control Policy to talk through the history of the opioid epidemic, fentanyl, and how the federal government is working with local communities to solve it.